Imron T. Aly is a trial lawyer who serves as lead counsel for clients on dozens of matters, and has first-chaired more than 10 trials. Imron is co-leader of Schiff Hardin’s Intellectual Property Group and co-chair of the firm's Hatch-Waxman and Biosimilars patent litigation team. His practice is focused on patent infringement litigation. He has litigated and tried patent infringement and other IP matters related to pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods, and financial trading systems.

Clients and leading industry publications describe Imron as a prepared courtroom advocate whose “tenacity sets him apart,” who “stands out for his pure advocacy skills,” and “is an untiring advocate for his clients’ cause.” In the 2020 Chambers USA guide, clients commended his litigation capabilities, saying, “He is very technically sophisticated, extraordinarily persuasive and an extremely effective trial counsel.”

Previous Experience

Prior to joining Schiff Hardin, Imron was an intellectual property partner in the Chicago office of an international law firm.

  • Experience

    • Fresenius Kabi USA, LLC v. FERA Pharmaceuticals, LLC (Successfully represented Fresenius Kabi USA, LLC in obtaining a rare preliminary injunction in federal district court. The injunction barred our client’s competitor from launching a generic version of its patented formulation of levothyroxine, an injectable thyroid hormone. The District Court for the District of New Jersey granted the injunction on the basis that our client was likely to win its patent lawsuit against its competitor.)
    • Vanda v. Lupin (Represent Lupin in iloperidone ANDA litigation)
    • Alcon v. Lupin (Represent Lupin in olopatadine ANDA litigation)
    • Horizon v. Lupin (Represent Lupin in naproxen/esomeprazole ANDA litigation)
    • BMS v. Lupin (Represent Lupin in apixaban ANDA litigation)
    • Sanofi v. Accord (Represent Accord in cabazitaxel ANDA litigation)
    • Forest Labs v. Hikma (Represented Hikma in trial for asenapine maleate ANDA litigation)
    • Cumberland Pharmaceuticals v. InnoPharma (Represented InnoPharma in acetylcysteine IV ANDA litigation)
    • Antares v. Medac (Represented Antares in medical device autoinjector patent litigation)
    • Cephalon v. Fresenius Kabi (Represented FK in arsenic trioxide ANDA litigation)
    • Onyx Pharma v. Fresenius Kabi (Represented FK in carfilzomib ANDA litigation)
    • Pfizer v. Fresenius Kabi (Represented FK in tigecycline 505(b)(2) trial)
    • Merck v. Fresenius Kabi (Represented FK in caspofungin 505(b)(2) trial)
    • Helsinn v. Fresenius Kabi (Represented FK in palonosetron ANDA litigation)
    • Celgene v. Fresenius Kabi (Represented FK in romidepsin ANDA litigation)
    • Mylan v. Fresenius Kabi (Represented FK in remifentanil ANDA litigation)
    • Shire Canada et al. v. Alkem Laboratories Ltd. (Represented Alkem in lanthanum carbonate ANDA litigation)
    • King Pharma Inc. and Meridian Medical Technologies Inc v. Teva Pharmaceuticals (Represented Teva in epinephrine injector ANDA litigation)
    • Aventis Pharma, S.A. and Sanofi-aventis Inc. v. Hospira Inc. (Represented Hospira including at trial in defending patent infringement claims for pharmaceutical involving docetaxel for cancer treatments)
    • Boehringer et al. v. Barr Laboratories (Represented Barr Laboratories in defending patent infringement claims for pharmaceutical involving dipyradimole for stroke prevention)
    • Sepracor Inc. v. Barr Laboratories Inc. (Represented Barr Laboratories in defending patent infringement claims for pharmaceutical involving levalbuterol for asthma treatments)
    • Maytag Corporation v. Whirlpool Corp. (Represented Whirlpool in defending patent infringement claims concerning mechanical dispensing systems technology)
    • Sears v. Bed Bath & Beyond (Represented Sears in patent case regarding electronic gift registry system)
    • Johnson Controls Inc. v. Lear Corp. (Represented Lear in patent case regarding remote control garage door opener circuitry and encryption)
    • Intellect Wireless v. Dell Inc. (Represented Dell in patent case involving cellular phone systems)
    • Nanogen Inc. v. Motorola Inc. (Represented Motorola in patent litigation concerning biomedical DNA hybridization microchip technology)
    • Computer Motion Inc. v. Intuitive Surgical Inc. (Represented Computer Motion in patent litigation concerning biomedical surgical robotics devices)
    • Oxford Gene Technology Ltd. v. Mergen Ltd. (Represented OGT in asserting patent infringement claims concerning DNA hybridization microarray biomedical technology)
    • Trading Technologies Intl. Inc. v. eSpeed Inc. (Representing eSpeed in defending patent infringement claims for a business-method patent concerning electronic futures trading)
    • International Game Technology Inc. v. Aristocrat Leisure Ltd. (Represented IGT in a patent litigation focusing on business-method patents for electronic funds management and ticketing systems)
  • Credentials


    • Georgetown University Law Center, J.D., 1999, magna cum laude
      Order of the Coif
      Georgetown Journal of Legal Ethics, Senior Articles Editor
    • Duke University, B.S.E., Biomedical Engineering, 1996, cum laude

    Bar Admissions

    • Illinois
    • Missouri
        • U.S. Patent and Trademark Office


          • Hon. Ann K. Covington, Missouri Supreme Court (1999-2000)

          Professional Memberships

          • Center for Biosimilars, Advisory Board, Member
          • Richard Linn American Inn of Court

          Teaching Appointments

          • Guest Lecturer, Patent Litigation, University of Michigan (2011, 2013)
        • Insights

          News Release

          Intellectual Property Group and Co-Leader Aly Honored for Hatch-Waxman Litigation

          Schiff Hardin LLP is pleased to announce that the firm’s Intellectual Property Practice Group has received the Impact Case of the Year award in 2020 by LMG Life Sciences for our ground-breaking patent-infringement victory in Fresenius Kabi v. Hospira.

          News Release

          Firm and Four Attorneys ranked in the 2020 IAM Patent 1000

          Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.

          In The News
          In The News
          News Release

          Managing IP Recognizes Three Schiff Hardin Attorneys as IP Stars 2020

          Schiff Hardin is pleased to announce that three Intellectual Property Practice Group attorneys have been recognized as IP Stars in Illinois for 2020 by Managing Intellectual Property.

          News Release

          Five Practice Areas and 19 Attorneys Ranked by Chambers USA 2020 Guide

          Schiff Hardin is pleased to announce that five practice areas have been ranked in Chambers USA 2020 guide, up one from 2019 with a first-time ranking for Energy & Natural Resources.


          COVID-19 Legal Issue Spotting for In-House Counsel

          Schiff Hardin LLP

          In The News
          News Release

          Eighty-Eight Attorneys Named to 2020 Leading Lawyers

          Schiff Hardin LLP is pleased to announce that 88 attorneys have been named to the 2020 Leading Lawyers list.

          News Release

          Thirty-Two Attorneys Named to 2020 Super Lawyers and Rising Stars Lists

          We are pleased to announce that 32 Schiff Hardin attorneys have been recognized on the 2020 Illinois Super Lawyers and Rising Stars lists.

          Other Publications

          • “Judge Allows Alternative Biologics Challenge,” Schiff Hardin Insight (Mar. 24, 2015)
          • “Myriad Faces Yet Another Patent Eligibility Battle In Return to the Federal Circuit,” Schiff Hardin Insight (Oct. 8, 2014)
          • “Encouraging Professionalism: The Magic Wand of the Patent Infringement Opinion,” Georgetown Journal of Legal Ethics (1999)
          • “Seller Beware: The Scope of the On Sale Bar after Pfaff v. Wells,” Texas Intellectual Property Law Journal (1999)

          Speeches & Presentations

          • COVID-19 Legal Issues Spotting for In-House Counsel,” Webinar (Apr. 1, 2020)
          • “Strategic Considerations When Managing and Protecting Disruptive Technologies,” Managing Intellectual Property Innovation and Litigation Summit 2019, San Francisco , Calif. (Jun. 11, 2019)
          • “New Developments in U.S. Hatch-Waxman Litigation,” IP Leadership Forum, New Delhi, India (2014)
          • “Business Method Patents,” Software & Information Industry Association, Financial Information Services Division (2002)
        • Citizenship

          Pro Bono Activities

          Imron has represented indigent clients in trademark and copyright, contract dispute, landlord-tenant, prisoner rights, and elder abuse matters.

          Civic and Charitable Memberships

          • Chicago Committee, Board Member
          • Metropolitan Tenants Organization, Former Board Member

        Product Liability and Mass Torts Blog

        FDA Issues Final Guidance on Biosimilars

        Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and... Continue Reading


        Clients Rely on Aly and Patel as Strategic Advisers to Bring Generic Drugs to Market

        image description

        Aly and Patel are Strategic, Must-Have Advisers Who Bring Generic Drugs to Market Copy: Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were featured in Leading Lawyers Magazine—2018 Business Edition for their successful track record in challenging giant pharmaceutical companies to bring generic drugs to the marketplace. MORE

        image description

        Pharma team scores rare preliminary injunction

        Schiff Hardin’s pharma and life sciences patent litigation team, led by partner Imron T. Aly, recently secured a preliminary injunction in federal court. Representing generic drug manufacturer Fresenius Kabi USA, LLC, our team convinced the judge to bar our client’s competitor from launching a generic version of levothyroxine, our client’s patented treatment formulation. MORE